MESA LABORATORIES INC (MLAB) Stock Fundamental Analysis
USA - NASDAQ:MLAB - US59064R1095 - Common Stock
70.6575 USD
-0.96 (-1.34%)
Taking everything into account, MLAB scores 4 out of 10 in our fundamental rating. MLAB was compared to 58 industry peers in the Life Sciences Tools & Services industry. MLAB has a medium profitability rating, but doesn't score so well on its financial health evaluation. MLAB is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
MLAB had negative earnings in the past year.
In the past year MLAB had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MLAB reported negative net income in multiple years.
In the past 5 years MLAB always reported a positive cash flow from operatings.
1.2 Ratios
MLAB's Return On Assets of -0.14% is fine compared to the rest of the industry. MLAB outperforms 67.24% of its industry peers.
The Return On Equity of MLAB (-0.36%) is better than 68.97% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.81%, MLAB is in the better half of the industry, outperforming 65.52% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for MLAB is significantly below the industry average of 13.56%.
The 3 year average ROIC (1.90%) for MLAB is below the current ROIC(3.81%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.36% | ||
| ROIC | 3.81% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)1.9%
ROIC(5y)1.6%
1.3 Margins
MLAB's Operating Margin of 5.70% is fine compared to the rest of the industry. MLAB outperforms 60.34% of its industry peers.
MLAB's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 62.12%, MLAB belongs to the top of the industry, outperforming 82.76% of the companies in the same industry.
In the last couple of years the Gross Margin of MLAB has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.7% | ||
| PM (TTM) | N/A | ||
| GM | 62.12% |
OM growth 3Y38.53%
OM growth 5Y0.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so MLAB is destroying value.
Compared to 1 year ago, MLAB has more shares outstanding
Compared to 5 years ago, MLAB has more shares outstanding
Compared to 1 year ago, MLAB has an improved debt to assets ratio.
2.2 Solvency
MLAB has an Altman-Z score of 0.82. This is a bad value and indicates that MLAB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.82, MLAB is not doing good in the industry: 60.34% of the companies in the same industry are doing better.
The Debt to FCF ratio of MLAB is 5.38, which is a neutral value as it means it would take MLAB, 5.38 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 5.38, MLAB is doing good in the industry, outperforming 68.97% of the companies in the same industry.
A Debt/Equity ratio of 0.46 indicates that MLAB is not too dependend on debt financing.
The Debt to Equity ratio of MLAB (0.46) is worse than 62.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 5.38 | ||
| Altman-Z | 0.82 |
ROIC/WACC0.39
WACC9.89%
2.3 Liquidity
MLAB has a Current Ratio of 0.66. This is a bad value and indicates that MLAB is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.66, MLAB is not doing good in the industry: 94.83% of the companies in the same industry are doing better.
MLAB has a Quick Ratio of 0.66. This is a bad value and indicates that MLAB is not financially healthy enough and could expect problems in meeting its short term obligations.
MLAB has a worse Quick ratio (0.47) than 94.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.66 | ||
| Quick Ratio | 0.47 |
3. Growth
3.1 Past
The earnings per share for MLAB have decreased strongly by -104.68% in the last year.
The earnings per share for MLAB have been decreasing by -39.16% on average. This is quite bad
The Revenue has grown by 11.47% in the past year. This is quite good.
The Revenue has been growing by 15.41% on average over the past years. This is quite good.
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
Revenue 1Y (TTM)11.47%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
3.2 Future
MLAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 231.94% yearly.
MLAB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.64% yearly.
EPS Next Y2471.86%
EPS Next 2Y369.85%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue Next Year3.51%
Revenue Next 2Y4.37%
Revenue Next 3Y4.64%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
MLAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
MLAB is valuated quite expensively with a Price/Forward Earnings ratio of 45.72.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MLAB is on the same level as its industry peers.
MLAB's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 34.62.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 45.72 |
4.2 Price Multiples
91.38% of the companies in the same industry are more expensive than MLAB, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, MLAB is valued cheaper than 98.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.55 | ||
| EV/EBITDA | 14.26 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MLAB may justify a higher PE ratio.
A more expensive valuation may be justified as MLAB's earnings are expected to grow with 231.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y369.85%
EPS Next 3Y231.94%
5. Dividend
5.1 Amount
MLAB has a yearly dividend return of 0.84%, which is pretty low.
MLAB's Dividend Yield is rather good when compared to the industry average which is at 0.48. MLAB pays more dividend than 100.00% of the companies in the same industry.
With a Dividend Yield of 0.84, MLAB pays less dividend than the S&P500 average, which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.84% |
5.2 History
The dividend of MLAB decreases each year by -0.50%.
MLAB has paid a dividend for at least 10 years, which is a reliable track record.
MLAB has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
5.3 Sustainability
The earnings of MLAB are negative and hence is the payout ratio. MLAB will probably not be able to sustain this dividend level.
DP-560.97%
EPS Next 2Y369.85%
EPS Next 3Y231.94%
NASDAQ:MLAB (11/18/2025, 3:00:57 PM)
70.6575
-0.96 (-1.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners96.24%
Inst Owner Change-11.84%
Ins Owners5.28%
Ins Owner Change13.36%
Market Cap388.62M
Revenue(TTM)240.98M
Net Income(TTM)-620.00K
Analysts80
Price Target90.27 (27.76%)
Short Float %7%
Short Ratio2.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.84% |
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP-560.97%
Div Incr Years0
Div Non Decr Years21
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-63.49%
Min EPS beat(2)-217.83%
Max EPS beat(2)90.84%
EPS beat(4)1
Avg EPS beat(4)-71.19%
Min EPS beat(4)-217.83%
Max EPS beat(4)90.84%
EPS beat(8)4
Avg EPS beat(8)363.88%
EPS beat(12)5
Avg EPS beat(12)215.08%
EPS beat(16)7
Avg EPS beat(16)149.42%
Revenue beat(2)0
Avg Revenue beat(2)-2.31%
Min Revenue beat(2)-3.63%
Max Revenue beat(2)-0.98%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)4.83%
Revenue beat(8)3
Avg Revenue beat(8)-0.52%
Revenue beat(12)4
Avg Revenue beat(12)-1.1%
Revenue beat(16)6
Avg Revenue beat(16)0.34%
PT rev (1m)0%
PT rev (3m)-26.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-40%
EPS NY rev (1m)0%
EPS NY rev (3m)0.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 45.72 | ||
| P/S | 1.6 | ||
| P/FCF | 11.55 | ||
| P/OCF | 10.16 | ||
| P/B | 2.25 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.26 |
EPS(TTM)-0.27
EYN/A
EPS(NY)1.55
Fwd EY2.19%
FCF(TTM)6.12
FCFY8.66%
OCF(TTM)6.96
OCFY9.85%
SpS44.06
BVpS31.36
TBVpS-20.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.36% | ||
| ROCE | 4.83% | ||
| ROIC | 3.81% | ||
| ROICexc | 4.12% | ||
| ROICexgc | N/A | ||
| OM | 5.7% | ||
| PM (TTM) | N/A | ||
| GM | 62.12% | ||
| FCFM | 13.89% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)1.9%
ROIC(5y)1.6%
ROICexc(3y)2.1%
ROICexc(5y)2.03%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.4%
ROCE(5y)2.02%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y106.13%
ROICexc growth 5Y21.15%
OM growth 3Y38.53%
OM growth 5Y0.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5Y2.57%
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 5.38 | ||
| Debt/EBITDA | 2.05 | ||
| Cap/Depr | 18.45% | ||
| Cap/Sales | 1.91% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 98.53% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.66 | ||
| Quick Ratio | 0.47 | ||
| Altman-Z | 0.82 |
F-Score5
WACC9.89%
ROIC/WACC0.39
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
EPS Next Y2471.86%
EPS Next 2Y369.85%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue 1Y (TTM)11.47%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
Revenue Next Year3.51%
Revenue Next 2Y4.37%
Revenue Next 3Y4.64%
Revenue Next 5YN/A
EBIT growth 1Y58.81%
EBIT growth 3Y51.48%
EBIT growth 5Y15.93%
EBIT Next Year171.2%
EBIT Next 3Y46.94%
EBIT Next 5YN/A
FCF growth 1Y-6.91%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y-6.04%
OCF growth 3Y6.07%
OCF growth 5Y11.64%
MESA LABORATORIES INC / MLAB FAQ
Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?
ChartMill assigns a fundamental rating of 4 / 10 to MLAB.
Can you provide the valuation status for MESA LABORATORIES INC?
ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.
How profitable is MESA LABORATORIES INC (MLAB) stock?
MESA LABORATORIES INC (MLAB) has a profitability rating of 6 / 10.
Is the dividend of MESA LABORATORIES INC sustainable?
The dividend rating of MESA LABORATORIES INC (MLAB) is 4 / 10 and the dividend payout ratio is -560.97%.